ArticleDrug safety2004
Safety related drug-labelling changes: findings from two data mining algorithms.
Article in Drug safety, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.Drug safety · 2009Pooled it
- Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: insights from FAERS and scRNA-seq data.Scientific reports · 2025Article
- Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system.Frontiers in oncology · 2025Article
- Article
- A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.Drug safety · 2016Article
- Evaluation of disproportionality safety signaling applied to healthcare databases.Drug safety · 2013Article
- A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.Drug safety · 2013Article
- Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.Drug safety · 2010Article
- Post-approval drug safety surveillance.Annual review of public health · 2010Review
- An evaluation of three signal-detection algorithms using a highly inclusive reference event database.Drug safety · 2009Article
- Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.Drug safety · 2009Article
- Impact of stratification on adverse drug reaction surveillance.Drug safety · 2008Article
- Stratification for spontaneous report databases.Drug safety · 2008Article
- Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned.British journal of clinical pharmacology · 2006Article
- Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.Drug safety · 2006Article
- Perspectives on the use of data mining in pharmaco-vigilance.Drug safety · 2005Review
- Data mining in pharmacovigilance: the need for a balanced perspective.Drug safety · 2005Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith increasing volumes of postmarketing safety surveillance data, data mining algorithms (DMAs) have been developed to search large spontaneous reporting system (SRS) databases for disproportional statistical dependencies between drugs and events. A crucial question is the proper deployment of such techniques within the universe of methods historically used for signal detection. One question of interest is comparative performance of algorithms based on simple forms of disproportionality analysis versus those incorporating Bayesian modelling. A potential benefit of Bayesian methods is a reduced volume of signals, including false-positive signals.
objectiveTo compare performance of two well described DMAs (proportional reporting ratios [PRRs] and an empirical Bayesian algorithm known as multi-item gamma Poisson shrinker [MGPS]) using commonly recommended thresholds on a diverse data set of adverse events that triggered drug labelling changes.
methodsPRRs and MGPS were retrospectively applied to a diverse sample of drug-event combinations (DECs) identified on a government Internet site for a 7-month period. Metrics for this comparative analysis included the number and proportion of these DECs that generated signals of disproportionate reporting with PRRs, MGPS, both or neither method, differential timing of signal generation between the two methods, and clinical nature of events that generated signals with only one, both or neither method.
resultsThere were 136 relevant DECs that triggered safety-related labelling changes for 39 drugs during a 7-month period. PRRs generated a signal of disproportionate reporting with almost twice as many DECs as MGPS (77 vs 40). No DECs were flagged by MGPS only. PRRs highlighted DECs in advance of MGPS (1-15 years) and a label change (1-30 years). For 59 DECs, there was no signal with either DMA. DECs generating signals of disproportionate reporting with only PRRs were both medically serious and non-serious. DISCUSSION/
conclusionIn most instances in which a DEC generated a signal of disproportionate reporting with both DMAs (almost twice as many with PRRs), the signal was generated using PRRs in advance of MGPS. No medically important events were signalled only by MGPS. It is likely that the incremental utility of DMAs are highly situation-dependent. It is clear, however, that the volume of signals generated by itself is an inadequate criterion for comparison and that clinical nature of signalled events and differential timing of signals needs to be considered. Accepting commonly recommended threshold criteria for DMAs examined in this study as universal benchmarks for signal detection is not justified.
Indexed as
Identifiers
15350157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.